Free Trial

Humana (HUM) Stock Forecast & Price Target

Humana logo
$255.23 +7.89 (+3.19%)
As of 05/20/2025 03:58 PM Eastern

Humana - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
17
Buy
7

Based on 24 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 17 have given a hold rating, and 7 have given a buy rating for HUM.

Consensus Price Target

$286.81
12.37% Upside
According to the 24 analysts' twelve-month price targets for Humana, the average price target is $286.81. The highest price target for HUM is $326.00, while the lowest price target for HUM is $250.00. The average price target represents a forecasted upside of 12.37% from the current price of $255.23.
Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

Sign Up

HUM Analyst Ratings Over Time

TypeCurrent Forecast
5/21/24 to 5/21/25
1 Month Ago
4/21/24 to 4/21/25
3 Months Ago
2/21/24 to 2/20/25
1 Year Ago
5/22/23 to 5/21/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
9 Buy rating(s)
Hold
17 Hold rating(s)
17 Hold rating(s)
19 Hold rating(s)
10 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$286.81$284.90$285.68$426.39
Forecasted Upside12.37% Upside15.78% Upside5.08% Upside19.91% Upside
Consensus Rating
Hold
Hold
Hold
Hold

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Humana Stock vs. The Competition

TypeHumanaMedical CompaniesS&P 500
Consensus Rating Score
2.29
2.81
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside12.37% Upside4,803.92% Upside13.04% Upside
News Sentiment Rating
Positive News

See Recent HUM News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/12/2025Truist Financial
2 of 5 stars
David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$325.00 ➝ $305.00+21.69%
5/1/2025Cantor Fitzgerald
3 of 5 stars
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$290.00 ➝ $290.00+11.86%
5/1/2025Oppenheimer
3 of 5 stars
Michael Wiederhorn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$300.00 ➝ $310.00+19.44%
5/1/2025Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Ransom
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$315.00+20.04%
4/15/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$270.00 ➝ $300.00+5.53%
4/11/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$270.00 ➝ $322.00+9.16%
4/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$326.00+18.49%
4/9/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$305.00 ➝ $316.00+12.60%
2/18/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lisa Gill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$257.00 ➝ $256.00-0.16%
2/12/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ben Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$283.00 ➝ $283.00+8.03%
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$301.00 ➝ $285.00+11.03%
1/15/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Tassan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$270.00 ➝ $288.00+2.82%
11/6/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$247.00 ➝ $308.00+18.16%
11/4/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Langston
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$261.00 ➝ $268.00+5.16%
11/4/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$387.00 ➝ $290.00+11.11%
10/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
10/9/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Fidel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$250.00 ➝ $250.00+2.35%
10/8/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Wilkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$308.00+30.36%
10/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$519.00 ➝ $253.00+5.40%
10/4/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$380.00 ➝ $250.00+3.31%
10/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$349.00 ➝ $250.00+3.70%
10/2/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/2/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$400.00 ➝ $250.00+6.05%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$450.00 ➝ $385.00+24.47%
3/13/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:08 AM ET.


Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 14, 2025. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Humana Inc.:

  • The current stock price is around $249.92, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid dividend yield of approximately 1.42%, providing a steady income stream for investors.
  • Recent analyst ratings show a mix of buy and hold recommendations, suggesting confidence in the company's future performance.
  • Humana Inc. has demonstrated consistent revenue growth, with an 8.4% increase year-over-year, reflecting its strong market position in the insurance industry.

Humana
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Humana Inc. for these reasons:

  • The stock has experienced volatility, with a 52-week range indicating significant price fluctuations, which may concern risk-averse investors.
  • Analysts have set varying price targets, with some indicating a potential decline, which could signal uncertainty about the stock's future performance.
  • Humana Inc. operates in a highly competitive market, which may impact its ability to maintain market share and profitability.
  • The company's debt-to-equity ratio of 0.68 suggests a moderate level of debt, which could pose risks if market conditions change.
  • Recent institutional selling activity, including a significant stake reduction by Colonial Trust Co SC, may indicate a lack of confidence among some investors.

HUM Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $286.81, with a high forecast of $326.00 and a low forecast of $250.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There are currently 17 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.

According to analysts, Humana's stock has a predicted upside of 12.37% based on their 12-month stock forecasts.

Over the previous 90 days, Humana's stock had 1 upgrade by analysts.

Humana has been rated by research analysts at Barclays, Cantor Fitzgerald, Guggenheim, Mizuho, Oppenheimer, Raymond James, Robert W. Baird, and Truist Financial in the past 90 days.

Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.


This page (NYSE:HUM) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners